文献速递主动脉疾病

新型嵌入式模块化单分支覆膜支架治疗累及左锁骨下动脉的B型主动脉夹层的前瞻性多中心研究

The Prospective, Multiple Center Study of a Novel Embedded Modular Single-Branched Stent-Graft for Type B Aortic Dissection Involving the Left Subclavian Artery.
PubMed 文献 · J Endovasc Ther · 2025-05-12

该多中心前瞻性研究纳入120例累及左锁骨下动脉的B型主动脉夹层患者,评估新型嵌入式模块化单分支覆膜支架的中期结局。技术成功率99.17%,30天死亡率0.83%,1年死亡率4.17%,分支段随访通畅率99.09%。作者认为中期结局令人鼓舞,但长期结局需关注和进一步研究。

要点

  • 技术成功率99.17%(119/120),仅1例因主动脉内膜-内膜套叠导致技术失败。
  • 30天主要并发症包括逆行性A型主动脉夹层2例(1.67%)、卒中3例(2.50%)、Ia型内漏6例(5.22%)。
  • 1年死亡率4.17%(5/120),分支段随访通畅率99.09%(109/110),12个月再干预率4.17%(5例)。

核心结论

  • 对于累及左锁骨下动脉的B型主动脉夹层患者,EMSBSG的中期结局令人鼓舞,是一种相对安全、有效且非定制化的血管内选择。
  • 长期结局值得关注并需进一步研究。

研究设计与样本

  • 多中心前瞻性临床试验,2020年12月至2021年11月在中国18家三级医院纳入120例接受EMSBSG治疗的B型主动脉夹层患者。
  • 术后1、6、12个月进行随访计算机断层血管造影扫描。

主要发现

  • 技术成功率为99.17%(119/120),仅1例技术失败归因于主动脉内膜-内膜套叠。
  • 30天死亡率为0.83%(1例)。
  • 30天主要并发症包括逆行性A型主动脉夹层2例(1.67%)、卒中3例(2.50%)、Ia型内漏6例(5.22%)。
  • 中位随访时间为12.84个月(范围11-16个月)。
  • 1年死亡率为4.17%(5/120),分支段随访通畅率为99.09%(109/110)。

临床怎么用

  • 作者认为,对于累及左锁骨下动脉的B型主动脉夹层患者,EMSBSG是一种相对安全、有效且非定制化的血管内选择,其中期结局令人鼓舞。
  • 作者指出,长期结局值得关注并需进一步研究。

局限性

  • 长期结局值得关注并需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to assess the midterm outcomes of a novel embedded modular single-branched stent-graft (EMSBSG) designed to preserve the left subclavian artery (LSA) of type B aortic dissection (TBAD). METHODS: From December 2020 to November 2021, a total of 120 patients with TBAD treated with an EMSBSG were enrolled in a multicenter prospective clinical trial at 18 Chinese tertiary hospitals. Follow-up computed tomography angiography scanning was conducted at 1, 6, and 12 months postprocedure. RESULTS: The technical success rate was 99.17% (n = 119/120), with only 1 technical failure attributed to aortic intimo-intimal intussusception. The 30-day mortality rate was 0.83% (n = 1). Thirty-day major complications included 2 cases (1.67%) of retrograde type A aortic dissection (RTAD), 3 cases (2.50%) of stroke, and 6 cases (5.22%) of Type Ia endoleaks. The median follow-up time was 12.84 (range, 11-16) months. The 1-year mortality rate was 4.17% (n = 5/120), and the follow-up patency rate of the branch section was 99.09% (n = 109/110). The overall 12-month reintervention rate was 4.17% (n = 5), including 3 RTAD cases, 2 Type I endoleaks, and 1 stent-induced new entry. CONCLUSION: For patients with TBAD involving the LSA, the midterm outcomes are encouraging for EMSBSG as a relatively safe, effective, and noncustomized endovascular option. However, long-term outcomes warrant attention and further investigation.Clinical ImpactThe midterm outcomes indicate that EMSBSG offers a safe, and effective endovascular option for preserving the LSA in patients with TBAD. The EMSBSG achieves LSA preservation through a non-customized endovascular solution, making it particularly suitable for emergency procedures. The core innovation of EMSBSG lies in its flexible, modular Embedded design, which adapts to the anatomical characteristics of TBAD in patients.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Xiong J, Zhang L, Yang M, et al. The Prospective, Multiple Center Study of a Novel Embedded Modular Single-Branched Stent-Graft for Type B Aortic Dissection Involving the Left Subclavian Artery. J Endovasc Ther. 2025. PMID: 40356328. doi:10.1177/15266028251330733

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。